JPRN-jRCT2031200362已完成1 期
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer
ocal Contact0 个研究点目标入组 212 人开始时间: 2021年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 212
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •1. Subject has provided informed consent prior to initiation of any study specific activities/procedures
- •2. Subjects with histologically or cytologically confirmed mCRPC who are refractory to a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the non-metastatic CRPC setting
- •3. Subjects must have undergone bilateral orchiectomy or must be on continuous ADT with a gonadotropin releasing hormone (GnRH) agonist or antagonist
- •4. Total serum testosterone 5. Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
- •- PSA level >/= 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart
- •- nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications
- •- appearance of 2 or more new lesions in bone scan
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- •7. Life expectancy >/= 6months
排除标准
- •1. Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for >/= 30 days prior to randomization are eligible
- •2. Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed with Amgen medical monitor prior to enrollment)
- •3, Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression
- •4. Active autoimmune disease or any other diseases requiring immunosuppressive therapy while on study
- •5. Needing chronic systemic corticosteroid therapy (prednisone > 10 mg per day or equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose
- •6. Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication, and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months of first dose of acapatamab
- •Part 2 only:
- •7. Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a Grade 3 or higher immune-related adverse event prior to first day of dosing
- •8. History or evidence of interstitial lung disease or active, non-infectious pneumonitis
- •Part 3 only:
- •9. Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of investigational product
- •Part 6 only:
- •Subjects are excluded from this cohort if any of the following additional criteria apply:
- •10. Use of any known inhibitors or inducers of drug-metabolizing enzymes within 30 days prior to study start and through start of cycle 3.
- •11. Use of the following components of the CYP phenotyping cocktail (midazolam HCl, warfarin sodium, vitamin K, omeprazole, and dextromethorphan HBr) within 14 days prior to cycle 1 day 1.
研究者
相似试验
招募中
1 期
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerProstate CancerJPRN-jRCT2031200384ocal Contact441
招募中
不适用
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)oat-cell carcinomasmall-cell carcinoma10029107Small Cell Lung CancerNL-OMON54787Amgen10
已完成
不适用
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-6463 when Administered to Healthy Volunteers as Single Ascending Doses with a Food Interaction Cohort, and as Multiple Ascending DosesAlzheimer's disease10057167DementiaNL-OMON47937Cyclerion Therapeutics, Inc.138
已完成
不适用
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Gastrointestinal AdenocarcinomaNL-OMON44202Amgen31
已完成
不适用
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen (PSMA) Half Life Extended (HLE) Bispecific T-cell Engager (BiTE) AMG 160 in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)Prostate CancerNL-OMON52552Amgen17